Financial Data and Key Metrics Changes - In Q4 2025, the company achieved organic constant currency sales growth of 5.4%, with full-year organic constant currency sales growth of 3.9% [15][19] - Adjusted earnings per share (EPS) for Q4 was $2.42, up 4.8% year-over-year, while full-year adjusted EPS was $8.20 [15][19] - Free cash flow for Q4 was $368 million, contributing to a total of $1.172 billion for the year, marking over 11% growth year-over-year [18][19] Business Line Data and Key Metrics Changes - The U.S. business grew by 5.7% on an organic constant currency basis, driven by new product momentum and strong robotic sales [16][19] - The international segment grew by 5% on an organic constant currency basis, supported by new product launches and strong robotic sales [16][19] - Specific product lines such as the Persona OsseoTi knee and Z1 hip stem saw significant growth, with U.S. NEE growth of 6% and U.S. hip growth of nearly 8% respectively [5][6] Market Data and Key Metrics Changes - The U.S. market remains a critical focus, representing 62%-63% of total revenue, with a need for improved productivity compared to competitors [81] - The company anticipates low single-digit organic constant currency revenue growth of 1%-3% for 2026, reflecting cautious optimism amid the sales force transition [19][20] Company Strategy and Development Direction - The company is transitioning to a dedicated and specialized U.S. sales channel to drive consistent growth, with expectations for completion by the end of 2027 [8][9] - Strategic priorities include enhancing people and culture, operational excellence, and innovation and diversification, with a focus on robotics and ambulatory surgical centers [10][11] - The company plans to prioritize returning capital to shareholders over M&A, with a buyback program of up to $1.5 billion approved [87][88] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing transformation and the potential for improved productivity and revenue growth, particularly in the U.S. market [81][82] - The company is closely monitoring the adoption of new products and international market performance, which are critical to achieving growth targets [36][37] Other Important Information - The company reported a GAAP-diluted EPS of $0.70 for Q4, down from $1.20 in the prior year, primarily due to restructuring charges and increased interest expenses [17] - Adjusted gross margin for Q4 was 72.4%, reflecting lower manufacturing costs and a favorable product mix [17] Q&A Session Summary Question: Impact of Salesforce Optimization Initiatives - Management detailed the transition to a dedicated sales force, emphasizing the need for specialization to improve productivity and competitive positioning, with expected benefits by the end of 2027 [26][32] Question: Guidance for 2026 Revenue Growth - Management explained that the guidance reflects uncertainties related to the sales force transition, new product adoption, and international market performance [35][36] Question: Pricing Erosion Expectations - The company anticipates up to 100 basis points of pricing erosion in 2026, influenced by market dynamics and regional pricing strategies [41][43] Question: Contribution from Paragon 28 - Management acknowledged that the contribution from Paragon 28 was slightly below expectations but remains optimistic about achieving double-digit growth in 2026 [73][76] Question: Confidence in Salesforce Transition - Management cited data-driven insights and benchmarking against competitors as the basis for confidence in the sales force transition, which is crucial for future growth [80][81]

Core Insights - The public fund issuance market has shown a strong recovery trend, with a total fundraising scale of 26.5 billion yuan during the week of November 3 to November 9, indicating a warming market sentiment [1][4] - Active equity products have become the dominant force in the issuance market, with stock and mixed funds raising a total of 21.8 billion yuan, accounting for 82.4% of the total issuance [1][2] - There is a notable increase in enthusiasm for overseas investments, highlighted by the establishment of two QDII funds focused on the Brazilian market, which collectively raised over 5.1 billion yuan [1][3] Fundraising Details - A total of 41 new funds were established during the week, with an average fundraising scale of 646 million yuan [1] - Among active equity funds, 21 stock funds raised 9.4 billion yuan (35.6%), while 9 mixed funds raised 12.4 billion yuan (46.8%), together exceeding 80% of the total issuance [1][2] - Bond funds raised 4.1 billion yuan (15.3%), while QDII funds raised 600 million yuan (2.3%) [1] Market Trends - The surge in active equity funds is attributed to improved market sentiment and increased risk appetite among investors, as well as proactive positioning by fund companies [2][4] - Leading institutions such as E Fund, Fortune, and Penghua have launched representative products, showcasing a variety of strategies including quantitative stock selection and industry themes [2] - The issuance of QDII funds targeting emerging markets like Brazil reflects a growing interest in international asset allocation opportunities [3]